<DOC>
	<DOC>NCT00375661</DOC>
	<brief_summary>The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.</brief_summary>
	<brief_title>Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Clinical diagnosis of Hepatocellular carcinoma due to Chronic Hepatitis C Virus Infection. Must be treated with curative treatment for primary tumor using either surgical resection or radiofrequency ablation therapy No recurrence of hepatocellular carcinoma 3 months after the primary treatment Renal dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
</DOC>